Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Antiviral Agents
/ blood
Area Under Curve
Carbamates
/ blood
Cohort Studies
Drug Therapy, Combination
Female
HIV Infections
Hepatitis C, Chronic
/ drug therapy
Humans
Imidazoles
/ blood
Male
Middle Aged
Pilot Projects
Prospective Studies
Pyrrolidines
/ blood
Sofosbuvir
/ blood
Valine
/ analogs & derivatives
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
19
09
2021
pubmed:
9
10
2021
medline:
29
3
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Sofosbuvir plus daclatasvir achieves high rates of sustained virologic response (SVR), with no differences according to HIV serostatus. However, only limited information is available on the pharmacokinetic variability of sofosbuvir and daclatasvir in HIV/HCV-coinfected patients. The aim of this study was to identify patient-, treatment-, and disease-related factors that are significantly associated with sofosbuvir and daclatasvir plasma trough concentrations (C In this observational cohort pilot study, HIV/HCV-coinfected patients undergoing sofosbuvir plus daclatasvir treatment were prospectively enrolled. Biochemical and viro-immunological parameters were assessed at baseline, week 4 (W4), end of treatment (EOT), and after EOT. The FIB-4 score and CKD-EPI equation were used to estimate liver disease and glomerular filtration rate (eGFR), respectively. For sofosbuvir, sofosbuvir metabolite (GS-331007), and daclatasvir, C Thirty-five patients were included (SVR 94%). An increased GS-331007 mean-C In HIV/HCV-coinfected patients in a real-world setting, exposure to a high GS-331007 C
Sections du résumé
BACKGROUND
BACKGROUND
Sofosbuvir plus daclatasvir achieves high rates of sustained virologic response (SVR), with no differences according to HIV serostatus. However, only limited information is available on the pharmacokinetic variability of sofosbuvir and daclatasvir in HIV/HCV-coinfected patients.
OBJECTIVES
OBJECTIVE
The aim of this study was to identify patient-, treatment-, and disease-related factors that are significantly associated with sofosbuvir and daclatasvir plasma trough concentrations (C
METHODS
METHODS
In this observational cohort pilot study, HIV/HCV-coinfected patients undergoing sofosbuvir plus daclatasvir treatment were prospectively enrolled. Biochemical and viro-immunological parameters were assessed at baseline, week 4 (W4), end of treatment (EOT), and after EOT. The FIB-4 score and CKD-EPI equation were used to estimate liver disease and glomerular filtration rate (eGFR), respectively. For sofosbuvir, sofosbuvir metabolite (GS-331007), and daclatasvir, C
RESULTS
RESULTS
Thirty-five patients were included (SVR 94%). An increased GS-331007 mean-C
CONCLUSIONS
CONCLUSIONS
In HIV/HCV-coinfected patients in a real-world setting, exposure to a high GS-331007 C
Identifiants
pubmed: 34623616
doi: 10.1007/s13318-021-00725-w
pii: 10.1007/s13318-021-00725-w
doi:
Substances chimiques
Antiviral Agents
0
Carbamates
0
Imidazoles
0
Pyrrolidines
0
Valine
HG18B9YRS7
daclatasvir
LI2427F9CI
Sofosbuvir
WJ6CA3ZU8B
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-142Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Navarro J, Laguno M, Vilchez HH, Guardiola JM, Carrion JA, Force L, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017;72:2850–6.
doi: 10.1093/jac/dkx223
Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus co-infection in the era of direct-acting antiviral agents: no longer a difficult to treat population. Hepatology. 2018;67:847–57.
doi: 10.1002/hep.29642
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25.
doi: 10.1056/NEJMoa1503153
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–84.
doi: 10.7326/0003-4819-147-10-200711200-00003
Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, et al. Eradication of HCV and non-liver-related non-AIDS-related events in HIV/HCV coinfection. Hepatology. 2017;66:344–56.
doi: 10.1002/hep.29071
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016;2017(66):153–94.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;2018(69):461–511.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H, European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218.
doi: 10.1016/j.jhep.2020.08.018
European Medicines Agency. Sovaldi, INN-sofosbuvir. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf . Accessed 14 Aug 2020
European Medicines Agency. Daklinza, INN-daclatasvir. Available online: Accessed 14 Aug 2020
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35.
doi: 10.1002/hep.27726
Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493–505.
doi: 10.1002/hep.28446
Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrière V, et al. Canadian Co-infection Cohort Study. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world? Clin Infect Dis. 2016;62:919–26.
Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39:589–611.
doi: 10.1007/s40264-016-0420-2
Taton A, Colson P, Dhiver C, Ruiz JM, Bregigeon S, Tomei C, et al. Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients. Antivir Ther. 2017;22:731–3.
doi: 10.3851/IMP3163
Notari S, Tempestilli M, Fabbri G, Libertone R, Antinori A, et al. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1073:183–90.
doi: 10.1016/j.jchromb.2017.12.018
Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, et al. Improvement of ALT decay kinetics by all-oral HCV treatment: role of NS5A inhibitors and differences with IFN-based regimens. PLoS ONE. 2017;12(5): e0177352.
doi: 10.1371/journal.pone.0177352
Liu CH, Lee MH, Lin JW, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. J Hepatol. 2020;72:839–46.
doi: 10.1016/j.jhep.2019.11.014
Dashti-Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. Expert Rev Clin Pharmacol. 2018;11:525–9.
doi: 10.1080/17512433.2018.1451327
Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Collaboration. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17:246.
doi: 10.1186/s12879-017-2350-8
Bifano M, Sevinsky H, Persson A, Chung E, Wind-Rotolo M, Hwang C, et al. Single-dose pharmacokinetics of daclatasvir (DCV; BMS-790052) in subjects with hepatic impairment compared with healthy subjects. In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA, 2011 Nov 6–9.
Virlogeux V, Choupeaux L, Pradat P, Maynard M, Bailly F, Scholtès C et al. Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: impact of drug concentration on viral load decay. Dig Liver Dis. 2016;48:1351–6.
doi: 10.1016/j.dld.2016.07.014
Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, et al. Population pharmacokinetic analysis of daclatasvir in subjects with chronic hepatitis C virus infection. Clin Pharmacokinet. 2017;56:1173–83.
doi: 10.1007/s40262-016-0504-2
Parisi SG, Loregian A, Andreis S, Nannetti G, Cavinato S, Basso M, et al. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. Int J Infect Dis. 2016;49:151–3.
doi: 10.1016/j.ijid.2016.06.020
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.
doi: 10.1086/321909
Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158:658–66.
doi: 10.7326/0003-4819-158-9-201305070-00604